SEC Form 4 · accession 0001144204-16-075186
TITAN PHARMACEUTICALS INC · TTNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sunil Bhonsle
Officer — President and CEO · Director
Period of report
Jan 11, 2016
Accepted (ET)
Jan 11, 2016 · 5:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000910267
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 11, 2016 | P | 17,000 | $3.18 | A | 107,974 | D | |
| Common StockF2 | holding | — | — | — | 54,684 | I | By Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average purchase price for the reported transactions. The range of prices for such transactions was $3.00 to $3.40. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2The reporting person serves as trustee of the family trust.